EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A Review of Methods Used to Assess Treatment Tolerability in Clinical Trials

Ari Gnanasakthy, Margaret Mordin, Jane Chang, Iyar Mazar, Amanda Di Rosa, Bidur Banjara, Jillian Lusk, Magdalena Harrington

The Patient - Patient-Centered Outcomes Research · 30.07.2026

DOI: 10.1007/s40271-026-00834-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Patient - Patient-Centered Outcomes Research, online erschienen am 30.07.2026. Verfasst von Ari Gnanasakthy und 7 weiteren Autor:innen. Beteiligte Einrichtung: RTI Health Solutions, Durham, NC, USA. gnanasakthy@rti.org. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Pfizer.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical tolerability refers to the degree to which patients can endure side effects without discontinuing treatment. Despite its frequent inclusion alongside efficacy and safety, tolerability in clinical trial publications is typically reported without a clear description of the methods used to assess it. We examined how treatment tolerability is evaluated in clinical trial publications. A targeted review of PubMed was conducted for publications of phase I, II, or III clinical trials published in 2024 and including tolerability in the title. Methods used to assess tolerability were extracted along with claims related to treatment tolerability. Of 339 identified publications, 154 met the inclusion criteria. Tolerability was referenced in the study objective or conclusion in ~95% of publications; fewer than half (n = 72 [46.8%]) reported these methods specifically in the methods section, and 38 (24.7%) reported tolerability findings. Over 85% of included studies implicitly or explicitly equated tolerability with safety. Clinical outcome assessments for tolerability were included in 22 trials (14.3%), with six incorporating preexisting clinical outcome assessment tools. Tolerability was predominantly described favorably, e.g., 'well tolerated' (n = 126 [85.7%]) or 'tolerable' (n = 17 [11.6%]). This review highlights opportunities to improve the scientific utility of tolerability data in clinical trial publications. Methods for assessing tolerability are often inconsistently described in publications and the terms safety and tolerability are frequently used interchangeably, which can obscure important distinctions. Future research should focus on developing methodological guidance and promoting clinical trial standards that clearly define how tolerability is assessed. Such advances will strengthen regulatory decision making, support clinical practice, and ultimately enhance patient care.

Autor:innen und Institutionen

  • RTI Health Solutions, Durham, NC, USA. gnanasakthy@rti.org.
  • RTI Health Solutions, Durham, NC, USA.
  • Pfizer, Inc., New York, NY, USA.

Förderung

  • Pfizer

Zitieren

APA

Gnanasakthy, A., Mordin, M., Chang, J., Mazar, I., Di Rosa, A., Banjara, B., Lusk, J., & Harrington, M. (2026). A Review of Methods Used to Assess Treatment Tolerability in Clinical Trials. The Patient - Patient-Centered Outcomes Research. https://doi.org/10.1007/s40271-026-00834-1

Vancouver

Gnanasakthy A, Mordin M, Chang J, Mazar I, Di Rosa A, Banjara B, et al. A Review of Methods Used to Assess Treatment Tolerability in Clinical Trials. The Patient - Patient-Centered Outcomes Research. 2026. doi:10.1007/s40271-026-00834-1

BibTeX
@article{Gnanasakthy2026,
  author = {Gnanasakthy, Ari and Mordin, Margaret and Chang, Jane and Mazar, Iyar and Di Rosa, Amanda and Banjara, Bidur and Lusk, Jillian and Harrington, Magdalena},
  title = {A Review of Methods Used to Assess Treatment Tolerability in Clinical Trials},
  journal = {The Patient - Patient-Centered Outcomes Research},
  year = {2026},
  doi = {10.1007/s40271-026-00834-1}
}
Kostenlos starten →